Q2 results showed fiscal responsibility alongside a robust financial position giving Nuvectis a strong springboard to continue driving its disruptive pipeline forward. Nuvectis Pharma (NASDAQ: NVCT) continues to affirm its position as a trailblazer in precision oncology, as highlighted in their Q2 2024 financial results and business updates. The company’s steadfast commitment to developing targeted […]
